ProCE Banner Activity

Key Takeaways on Improving Renal and Cardiovascular Outcomes in Patients with CKD and T2D

Clinical Thought

An expert reviews important considerations for chronic kidney disease (CKD) screening, cardiovascular risk, and how to integrate the recently approved therapy, finerenone, into the management of patients with type 2 diabetes and CKD.

Released: June 07, 2022

Expiration: June 06, 2023

No longer available for credit.



George L. Bakris

George L. Bakris, MD

Professor of Medicine
American Heart Association Comprehensive Hypertension Center
Department of Medicine
University of Chicago Medicine
Chicago, Illinois


This activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.

Provided by

ProCE Banner


Bayer HealthCare Pharmaceuticals Inc.

Target Audience

NPs and PAs in primary care


George L. Bakris, MD: consultant/advisor/speaker: Alnylam, AstraZeneca, Bayer, DiaMedica Therapeutics, Horizon, Ionis, KBP Biosciences, Merck, Novo Nordisk, Quantum Genomics.


Clinical Thought


The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.

Additional Information

Program Medium

This program has been made available online.